Frequencies of VKORC1-1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population

被引:0
作者
Rathore, Saurabh S. [1 ]
Agarwal, Surendra K.
Pande, Shantanu
Mittal, Tulika [1 ]
Mittal, Balraj [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Genet, Lucknow 226014, Uttar Pradesh, India
关键词
VKORC1; CYP2C9; polymorphism; genotype; allele frequency; North Indians; K EPOXIDE REDUCTASE; DOSE REQUIREMENT; WARFARIN; CYP2C9; POLYMORPHISM; PHARMACOGENETICS; ASSOCIATION; THERAPY;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Dose requirements for oral anticoagulants in thromboembolic events are influenced by polymorphisms in VKORC1 and CYP2C9 genes. The Indian population comprises multiple ethnic groups but no data is available on allele frequencies of these genes for North Indians. The present study aimed at establishing the allele and genotype frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 alleles in the North Indian population. One hundred and two healthy subjects from the Northern Indian region were genotyped for VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 by polymerase chain reaction and restriction fragment length polymorphism. Allele frequencies were compared with that of the HapMap populations. The allele frequencies for VKORC1 -1639 A, CYP2C9*2 and CYP2C9*3 were found to be 14.22%, 4.90% and 3.92% respectively. This report also describes the inter-ethnic differences in the Northern Indian frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 alleles with that of other populations and HapMap project data. VKORC1 -1639 G>A allele is present at moderately high frequency in the Northern Indian population. The frequencies of CYP2C9*2 and CYP2C9*3 alleles are also found to be different from other populations.
引用
收藏
页码:333 / 337
页数:5
相关论文
共 20 条
[1]   Allele and genotype frequency of CYP2C9 in Tamilnadu population [J].
Adithan, C ;
Gerard, N ;
Vasu, S ;
Balakrishnan, R ;
Shashindran, CH ;
Krishnamoorthy, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) :707-709
[2]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[3]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[4]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[5]  
*CYP ALL NOM COMM, CYP2C9 ALL NOM
[6]   Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy [J].
Furuya, H ;
FernandezSalguero, P ;
Gregory, W ;
Taber, H ;
Steward, A ;
Gonzalez, FJ ;
Idle, JR .
PHARMACOGENETICS, 1995, 5 (06) :389-392
[7]   Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].
Higashi, MK ;
Veenstra, DL ;
Kondo, LML ;
Wittkowsky, AK ;
Srinouanprachanh, SL ;
Farin, FM ;
Rettie, AE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698
[8]   CYP2C9 and CYP2C19 genetic polymorphisms:: frequencies in the south Indian population [J].
Jose, R ;
Chandrasekaran, A ;
Sam, SS ;
Gerard, N ;
Chanolean, S ;
Abraham, BK ;
Satyanarayanamoorthy, K ;
Peter, A ;
Rajagopal, K .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (01) :101-105
[9]   Pharmacogenetics of Warfarin [J].
Kamali, Farhad ;
Wynne, Hilary .
ANNUAL REVIEW OF MEDICINE, 2010, 61 :63-75
[10]  
Lee MTM, 2009, PHARMACOGENOMICS, V10, P1609, DOI [10.2217/pgs.09.80, 10.2217/PGS.09.80]